Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.46 |
| ▸ | HTR2C | P28335 | 5/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 2/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1973604 | 0.84 | HTR6 (0.59) | HTR6DRD2HTR1A | |
| SCHEMBL2274416 | 0.83 | CYP3A4 (0.54) | HTR6HTR2CKCNH2HTR2ACYP3A4 | |
| SCHEMBL1975081 | 0.82 | HTR6 (0.53) | HTR6HTR2CKCNH2HTR2ACYP3A4 | |
| SCHEMBL1972934 | 0.82 | HTR6 (0.59) | HTR6HTR2CKCNH2HTR2ACYP3A4 | |
| SCHEMBL2271622 | 0.79 | CYP3A4 (0.66) | HTR6HTR2CKCNH2HTR2ACYP3A4 | |
| Hydrochloric Acid SCHEMBL1975102 | 0.77 | HTR6 (0.58) | HTR6KCNH2 | |
| SCHEMBL2271799 | 0.75 | HTR6 (0.55) | HTR6HTR2CKCNH2HTR2ACYP3A4 | |
| SCHEMBL1973239 | 0.74 | HTR6 (0.60) | HTR6HTR2CKCNH2HTR2ACYP3A4 | |
| SCHEMBL1972822 | 0.74 | HTR6 (0.56) | HTR6DRD2HTR7HTR1A | |
| SCHEMBL1980883 | 0.73 | HTR6 (0.58) | HTR6KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155674-A1 | AMINOALKOXY ARYL SULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | Suven Life Sciences Limited (IN) | 2010-02-24 | — | — | EP | claimed |
| WO-2008136017-A1 | AMINOALKOXY ARYL SULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2008-11-13 | — | — | WO | claimed |
| US-8003670-B2 | Aminoalkoxy aryl sulfonamide compounds and their use as 5-HT6 ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-08-23 | — | — | US | disclosed |
| EP-2155674-B1 | AMINOALKOXY ARYL SULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2011-06-22 | — | — | EP | disclosed |
| US-20100087484-A1 | AMINOALKOXY ARYL SULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-04-08 | — | — | US | disclosed |
| EP-2155674-A1 | AMINOALKOXY ARYL SULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | Suven Life Sciences Limited (IN) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008136017-A1 | AMINOALKOXY ARYL SULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087484-A1 | AMINOALKOXY ARYL SULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR5A, HTR1B | HTR6 1/4885HTR2C 4/4885KCNH2 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.